Saptalis Pharma LLC v. MSN Pharma Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Saptalis Pharmaceuticals, LLC (New York) and Appili Therapeutics Inc. (Canada)
  • Defendant: MSN Pharmaceuticals, Inc. (Delaware) and MSN Laboratories Pvt. Ltd. (India)
  • Plaintiff’s Counsel: McCarter & English, LLP; Husch Blackwell LLP
• Case Identification: 2:26-cv-01084, D.N.J., 02/03/2026
• Venue Allegations: Venue is alleged to be proper for MSN Pharmaceuticals, Inc. based on its principal place of business in the District of New Jersey. Venue for MSN Laboratories Pvt. Ltd. is based on its status as a foreign entity, which may be sued in any judicial district, and on the fact that a legally operative notice letter was sent from within the district on behalf of both defendants.
• Core Dispute: Plaintiffs allege that Defendants’ submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic oral suspension of metronidazole constitutes an act of infringement of two patents covering taste-masked formulations of the drug.
• Technical Context: The technology concerns pharmaceutical formulations designed to mask the bitter taste of metronidazole, an antimicrobial drug, to improve patient compliance, particularly in populations with difficulty swallowing tablets, such as pediatric and geriatric patients.
• Key Procedural History: This is a Hatch-Waxman action initiated in response to Defendants' submission of ANDA No. 221087 and an accompanying Paragraph IV certification asserting that Plaintiffs' patents are invalid, unenforceable, and/or would not be infringed by the proposed generic product. The patents-in-suit are listed in the FDA's "Orange Book" in connection with Plaintiffs' approved drug product, LIKMEZ®.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,541,035 - “Oral Formulations of Metronidazole and Methods of Treating an Infection Using Same”

The Invention Explained

• Problem Addressed: The patent describes the difficulty in administering the antimicrobial drug metronidazole due to its bitter and unpleasant metallic aftertaste, which leads to poor patient compliance Compl. ¶26 ’035 Patent, col. 1:45-49 For patients who cannot swallow pills, such as children, crushing tablets is a common but unpalatable solution, and alternative liquid formulations like metronidazole benzoate are not therapeutically equivalent for acute infections due to slower absorption ’035 Patent, col. 2:55-61
• The Patented Solution: The invention is an oral pharmaceutical composition, preferably a liquid suspension, that uses magnesium aluminum silicate as a suspending and taste-masking agent ’035 Patent, abstract The specification suggests that the silicate’s clay-like structure may trap metronidazole molecules and increase the formulation's viscosity, limiting contact between the bitter drug and the patient's taste buds while maintaining a pharmacokinetic profile suitable for treating acute infections ’035 Patent, col. 18:49-61
• Technical Importance: This approach aimed to provide the first oral liquid metronidazole formulation that was both palatable and bioequivalent to the immediate-release tablet form, thereby improving dosing adherence without compromising therapeutic efficacy ’035 Patent, col. 2:9-14

Key Claims at a Glance

The complaint alleges infringement of "one or more claims" without further specification Compl. ¶39 Independent claim 1 is representative of the composition claims.

• Independent Claim 1: An oral pharmaceutical composition comprising:
  • metronidazole,
  • sucrose,
  • glycerin,
  • purified water,
  • magnesium aluminum silicate,
  • microcrystalline cellulose,
  • sucralose,
  • sodium phosphate,
  • one or more preservatives,
  • strawberry flavoring agent, and
  • peppermint flavoring agent.
    The complaint does not explicitly reserve the right to assert dependent claims.

U.S. Patent No. 12,257,236 - “Oral Formulations of Metronidazole and Methods of Treating an Infection Using Same”

The Invention Explained

• Problem Addressed: As a continuation of the application leading to the ’035 Patent, the ’236 Patent addresses the same technical problems related to the bitterness and poor palatability of existing metronidazole formulations ’236 Patent, col. 1:45-49
• The Patented Solution: The ’236 Patent claims methods of using the taste-masked formulation described in the ’035 Patent. The core technological solution remains the use of magnesium aluminum silicate in a liquid suspension to improve the taste of metronidazole while ensuring therapeutic equivalence to solid oral dosage forms ’236 Patent, abstract ’236 Patent, col. 18:49-61
• Technical Importance: By claiming the method of use, this patent extends protection beyond the composition itself to the act of administering the specific formulation to treat infections, a common claiming strategy in pharmaceutical patenting.

Key Claims at a Glance

The complaint alleges infringement of "one or more claims" without further specification Compl. ¶61 Independent claim 1 is representative of the method of treatment claims.

• Independent Claim 1: A method of treating an infection in a patient, said method comprising the step of administering to the patient an effective amount of an oral pharmaceutical liquid suspension comprising:
  • a) metronidazole or a pharmaceutically acceptable salt thereof; and
  • b) magnesium aluminum silicate, wherein the magnesium aluminum silicate is a natural product.
    The complaint does not explicitly reserve the right to assert dependent claims.

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is Defendants' proposed generic "metronidazole oral suspension, 500 mg/5 mL," referred to as the "MSN ANDA Product" Compl. ¶5

Functionality and Market Context

• The complaint alleges that the MSN ANDA Product is a generic version of Plaintiffs' LIKMEZ® product Compl. ¶31 By filing an ANDA, Defendants have represented to the FDA that their product will have the same active ingredient, dosage form, strength, and method of administration as LIKMEZ®, and that it will be bioequivalent Compl. ¶32 The action is based on the statutory act of infringement under 35 U.S.C. § 271(e)(2), which is the submission of the ANDA itself to seek approval for commercialization prior to patent expiry Compl. ¶30 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

11,541,035 Patent Infringement Allegations

12,257,236 Patent Infringement Allegations

• Identified Points of Contention: The infringement analysis will likely focus on the precise composition of the MSN ANDA Product, which is not detailed in the complaint.
  • Scope Questions: A central question may be whether the term "magnesium aluminum silicate" in the ’035 Patent’s claims covers the specific type of silicate used by MSN. For the ’236 Patent, a key dispute will likely be whether MSN's silicate qualifies as a "natural product" as required by claim 1.
  • Technical Questions: A primary point of contention will be factual: does the formulation described in MSN’s confidential ANDA submission contain every ingredient recited in claim 1 of the ’035 Patent? Defendants' Paragraph IV certification that their product would not infringe suggests they may argue that their formulation omits at least one claimed component or uses a non-equivalent substitute Compl. ¶33

V. Key Claim Terms for Construction

• The Term: "magnesium aluminum silicate" (’035 Patent, Claim 1; ’236 Patent, Claim 1)

• Context and Importance: This excipient is central to the invention's taste-masking function. The definition of this term is critical because if MSN's formulation uses a compound that falls outside the proper construction of "magnesium aluminum silicate," it may not infringe. Practitioners may focus on this term as Defendants will likely argue their chosen silicate is technically distinct from what is claimed.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification describes the term broadly as a "blend of colloidal montmorillonite and saponite" and notes it can be a "natural product" or "synthetic" ’035 Patent, col. 18:31-33 '035 Patent, col. 4:1-4 This language may support a construction that encompasses a variety of compounds meeting that general description.
  • Evidence for a Narrower Interpretation: The specification repeatedly references specific commercial grades, such as "VEEGUM™ brand" and particularly "VEEGUM™ HV" (Type 1C), and provides a table detailing the properties of different types ’035 Patent, col. 4:5 '035 Patent, col. 11:19-21 '035 Patent, Table A This could support an argument that the claims are implicitly limited to the specific types of silicate disclosed and tested.

• The Term: "natural product" (’236 Patent, Claim 1)

• Context and Importance: This term expressly limits claim 1 of the ’236 Patent. Infringement of this claim hinges on whether the magnesium aluminum silicate used in the MSN ANDA Product is sourced or manufactured in a way that qualifies it as a "natural product."

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The patent does not provide an explicit definition of "natural product." A party might argue for its plain and ordinary meaning, which could encompass any substance derived from mineral sources with minimal processing.
  • Evidence for a Narrower Interpretation: The specification explicitly distinguishes between natural and synthetic silicates, referencing "Veegum™ (Vanderbilt Minerals)" as an example of a natural product and "Neusilin™" as a synthetic one ’035 Patent, col. 18:35-56 '035 Patent, col. 4:1-4 This express distinction suggests that the term is intended to exclude man-made or chemically synthesized silicates, potentially creating a clear line for non-infringement if MSN uses a synthetic variant.

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement for both the ’035 and ’236 patents. Inducement is predicated on the allegation that MSN, with knowledge of the patents, will instruct and encourage infringement by doctors and patients through its product labeling and package inserts Compl. ¶¶40-41 Compl. ¶¶62-63 Contributory infringement is based on the allegation that the MSN ANDA Product is a material part of the patented invention and is not a staple article of commerce suitable for substantial non-infringing use (Compl. ¶¶43, 65).
• Willful Infringement: While the complaint does not use the term "willful," it alleges that Defendants have been aware of the patents and have "no reasonable basis for believing" that their product will not infringe (Compl. ¶¶45, 67). These allegations provide a basis for a later claim of willful infringement, which could support a request for enhanced damages.

VII. Analyst’s Conclusion: Key Questions for the Case

The resolution of this case will likely depend on the answers to a few central questions:

• A primary issue will be one of compositional identity: Does the confidential formulation in MSN's ANDA contain every single excipient recited in the asserted composition claims of the ’035 Patent? The non-infringement defense will likely turn on proving a meaningful difference in formulation.
• A key question of claim scope will be determinative for the ’236 Patent: Does the magnesium aluminum silicate used in MSN's product meet the claim limitation of being a "natural product," as distinguished from synthetic alternatives in the patent's own specification?
• Finally, if literal infringement is not found, an evidentiary question of technical equivalence will arise: If MSN has substituted any claimed ingredients, do those substitutes perform substantially the same function in substantially the same way to achieve the same result as the claimed ingredients, particularly with respect to the novel taste-masking function?